Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: A systematic review and meta-analysis.

This meta-analysis was performed to resolve the inconsistencies regarding resistin and follistatin levels in women with polycystic ovary syndrome (PCOS) by pooling the available evidence. A systematic literature search using PubMed and Scopus was carried out through November 2020 to obtain all pertinent studies. Weighted mean differences (WMDs) with corresponding 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between the levels of resistin and follistatin with PCOS in the overall and stratified analysis by obesity status. A total of 47 publications, 38 for resistin (2424 cases; 1906 controls) and 9 studies for follistatin (815 cases; 328 controls), were included in the meta-analysis. Resistin levels were significantly higher in PCOS women compared with non-PCOS controls (WMD = 1.96 ng/ml; 95%CI = 1.25-2.67, P≤0.001) as well as in obese PCOS women vs. obese controls, and in non-obese PCOS women compared with non-obese controls, but not in obese PCOS vs. non-obese PCOS patients,. A significantly increased circulating follistatin was found in PCOS patients compared with the controls (WMD = 0.44 ng/ml; 95%CI = 0.30-0.58, P≤0.001) and in non-obese PCOS women compared with non-obese controls and in obese PCOS women vs. obese controls, but, no significant difference in follistatin level was observed in obese PCOS compared with non-obese PCOS women. Significant heterogeneity and publication bias was evident for some analyses. Circulating levels of resistin and follistatin, independent of obesity status, are higher in women with PCOS compared with controls, showing that these adipokines may contribute to the pathology of PCOS.

Folate conjugated hyaluronic acid coated alginate nanogels encapsulated oxaliplatin enhance antitumor and apoptosis efficacy on colorectal cancer cells (HT29 cell line).

Oxaliplatin (OXA) has been widely used for treatment of colorectal cancer. In this study, to enhance antitumor and apoptosis efficacy, OXA was encapsulated in a novel folate conjugated hyaluronic acid coated alginate nanogels (F/HA/AL/OXA). The F/HA/AL/OXA nanogels were prepared by cross-linking process. The physico-chemical properties of F/HA/AL/OXA nanogels were characterized using scanning electron microscopy, transmission electron microscopy, fourier transform infrared spectroscopy, dynamic light scattering, and fluorescent spectrophotometry. The in-vitro antitumor activity of free OXA, AL, HA/AL, HA/AL/OXA and F/HA/AL/OXA nanogels were assessed using MTT assay against colorectal cancer cells (HT29 cell line). Finally, the effect of F/HA/AL/OXA nanogels on genes expression of Bax and Bcl2 was evaluated using quantitative real-time polymerase chain reaction (qRT-PCR) technique. The F/HA/AL/OXA nanogels were 200.3 nm in diameter and had a zeta potential of -22.0 mv. Antitumor activity of F/HA/AL/OXA nanogels on HT29 cell line indicated the highest antitumor activity as compared to free OXA and the empty nanogels. Compared to free OXA and the empty nanogels, the expression of Bax in HT29 cells treated with F/HA/AL/OXA nanogels was significantly increased along with suppression of Bcl-2 (p < .01). In general, the present F/HA/AL/OXA nanogels are a promising carrier candidate for OXA to improve the anti-tumor activity.